News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News May 21, 2026
Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement
Gibson Dunn is advising Mentari Therapeutics, Inc. on its merger with InMed Pharmaceuticals, Inc. and concurrent $290 million private placement.
Firm News April 28, 2026
Gibson Dunn Advises XOMA Royalty on Sale to Ligand Pharmaceuticals
Gibson Dunn is advising XOMA Royalty on its sale to Ligand Pharmaceuticals Inc.
Firm News April 7, 2026
Gibson Dunn Advises Korsana Biosciences on Merger with Cyclerion Therapeutics
Gibson Dunn is advising Korsana Biosciences on its merger with Cyclerion Therapeutics, Inc. and concurrent $380 million financing.
Firm News March 3, 2026
Gibson Dunn Advises Gyre Therapeutics on Its Acquisition of Cullgen
Gibson Dunn is advising Gyre Therapeutics, Inc., an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, on its acquisition of Cullgen Inc. The all-stock transaction is valued at approximately $300 million.
Firm News December 17, 2025
Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings
Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings
Firm News November 19, 2025
Gibson Dunn Advising XOMA Royalty on XenoTherapeutics and Xeno Acquisition’s Purchase of Repare Therapeutics
Gibson Dunn is advising XOMA Royalty on XenoTherapeutics, Inc. and Xeno Acquisition Corp.’s acquisition of Repare Therapeutics Inc.
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News August 21, 2025
Gibson Dunn Advises XOMA Royalty on Acquisition of Mural Oncology
Gibson Dunn is advising XOMA Royalty Corporation on its acquisition of Mural Oncology plc